Susquehanna International Group
BLRX

Susquehanna International Group’s BioLineRX BLRX Stock Holding History

Susquehanna International Group’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.6K Buy
+10,200
New +$28.6K ﹤0.01% 12824
2024
Q1 		– Sell
-2,000
Closed -$126K – 12194
2023
Q4 		$126K Buy
+2,000
New +$124K ﹤0.01% 11138

Other funds holding BLRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna International Group's BLRX Position: Q3 2025 in Review

Susquehanna International Group sold out of BioLineRX (BLRX) in Q3 2025, closing a stake of 11,098 shares — an estimated $44.5K sold.

Susquehanna International Group first reported a position in BLRX in Q1 2016 and held it in 18 quarters. The position peaked at $1.39M in Q1 2017. 14 funds tracked by Wall St. Rank hold BLRX as of Q3 2025.

  • Susquehanna International Group reported no remaining BioLineRX position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 11,098 BioLineRX shares in Q3 2025, an estimated $44.5K.
  • Susquehanna International Group first reported a position in BioLineRX in Q1 2016 and held it in 18 quarters.
  • Susquehanna International Group's BioLineRX position peaked at $1.39M in Q1 2017.
  • 14 funds tracked by Wall St. Rank held BioLineRX as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.